dc.creator | Giner García, Mercedes | es |
dc.creator | Vázquez Gámez, María de los Ángeles | es |
dc.creator | Miranda, María José | es |
dc.creator | Bocio-Núñez, Jesús | es |
dc.creator | Olmo-Montes, Francisco Jesús | es |
dc.creator | Rico Corral, Miguel Ángel | es |
dc.creator | Colmenero, Miguel Ángel | es |
dc.creator | Montoya García, María José | es |
dc.date.accessioned | 2023-07-05T12:34:27Z | |
dc.date.available | 2023-07-05T12:34:27Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Giner García, M., Vázquez Gámez, M.d.l.Á., Miranda, M.J., Bocio-Núñez, J., Olmo-Montes, F.J., Rico Corral, M.Á.,...,Montoya García, M.J. (2022). Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment. Journal of Clinical Medicine (JCM), 11 (16), 4749. https://doi.org/10.3390/jcm11164749. | |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://hdl.handle.net/11441/147743 | |
dc.description.abstract | Circulating osteogenic precursor (COP) cells are peripheral blood cells with a capacity for
osteogenesis. The objective of our study was to ascertain the percentage of COPs as an early biomarker
of osteoporosis and the effect of these cells in response to Denosumab (DmAb) (anti-resorptive) or to
Teriparatide (TPDP) (anabolic) as very effective drugs in the treatment of the illness. A first study was
conducted on healthy volunteers, with three age ranges, to determine the percentage of COPs and
relate it to their anthropometric and biochemical characteristics, followed by a second longitudinal
study on patients with osteoporosis, whereby one group of patients was treated with TPTD and
another with DmAb. All were analyzed by cytometry for COP percentage in blood, bone turnover
markers, and bone mass. Our findings show that COPs are influenced by age and become more
prolific in the stages of growth and skeletal maturation. A higher percentage of COPs is found in
osteoporotic disease, which could constitute a predictive marker thereof. We also show how treatment
with TPTD or DmAb mobilizes circulating osteogenic precursors in the blood. Significant increases
in % COPs were observed after 12 months of treatment with Dmb (21.9%) and TPTD (17%). These
results can be related to an increase in osteogenesis and, consequently, a better and more efficient
repair of bone tissue. | es |
dc.format | application/pdf | es |
dc.format.extent | 10 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Journal of Clinical Medicine (JCM), 11 (16), 4749. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Circulating osteogenic progenitor cells | es |
dc.subject | Osteoporosis | es |
dc.subject | Metabolic bone disorders | es |
dc.subject | Teri paratide | es |
dc.subject | Denosumab | es |
dc.title | Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/11/16/4749 | es |
dc.identifier.doi | 10.3390/jcm11164749 | es |
dc.journaltitle | Journal of Clinical Medicine (JCM) | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 16 | es |
dc.publication.initialPage | 4749 | es |